Clinical trial readout dates for Protagonist Therapeutics Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$8.8B
Cash & investments$835Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-05
In progress, no date published
Phase 3Icotrokinra
Psoriatic Arthritis
date not published
Trial Planned
Phase 2PN-235 (JNJ-77242113)
Inflammatory bowel diseases (IBD)
date not published
Trial Planned
Phase 2Rusfertide (PTG-300)
Hereditary hemochromatosis
date not published
Trial Planned
Cash position
Protagonist Therapeutics Inc. reported $835M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-06). It reported net income of $220M for that quarter.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates